Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01272102 · ClinicalTrials.gov registry record
Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma
A clinical trial of Glaucoma, sponsored by Carl Zeiss Meditec.
- Completed
- Registry status
- 119
- Enrollment target
- 4
- Study locations
NCT01272102 is a study of Glaucoma that has completed, run by Carl Zeiss Meditec. The registered enrollment target is 119 participants, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01272102, a study of Glaucoma, has completed, sponsored by Carl Zeiss Meditec.
- COMPLETED
- Registry status
- 119 participants
- Enrollment target
- 4
- Study locations
Study Summary
To determine the area under the Receiver Operator Characteristic Curve (AUC) for the Ganglion Cell Analysis (GCA) average thickness.
Conditions Studied
Study Locations (4)
California
- Stanford Eye Institute - Palo Alto
Florida
- Bascom Palmer Eye Institute - Miami
Texas
- Glaucoma Associates of Texas - Dallas
Utah
- Utah Eye Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01272102
The ClinicalTrials.gov registry entry for NCT01272102 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (87% lower). The listed sponsor is Carl Zeiss Meditec, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 0 interventions.
NCT01272102 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT01272102 about?
NCT01272102 is a clinical study titled "Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma". To determine the area under the Receiver Operator Characteristic Curve (AUC) for the Ganglion Cell Analysis (GCA) average thickness.
What is the current status of trial NCT01272102?
This trial is currently completed. The enrollment target is 119 participants. The study started on 2010-11. Estimated completion is 2011-03.
What conditions does trial NCT01272102 study?
This clinical trial studies the following conditions: Glaucoma.
Who is sponsoring clinical trial NCT01272102?
This trial is sponsored by Carl Zeiss Meditec, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01272102 being conducted?
This trial has 4 study locations across California, Florida, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Functional and Structural Imaging for Glaucoma
RECRUITING
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Eye Pressure Lowering Surgery
RECRUITING
-
Tolerability of an Anesthesia-free Tonometer Tip
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.